<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03988452</url>
  </required_header>
  <id_info>
    <org_study_id>JC3218</org_study_id>
    <nct_id>NCT03988452</nct_id>
  </id_info>
  <brief_title>Nucleosides And Darunavir/Dolutegravir In Africa</brief_title>
  <acronym>NADIA</acronym>
  <official_title>Nucleosides And Darunavir/Dolutegravir In Africa (NADIA): a Randomised Controlled Trial of Darunavir Versus Dolutegravir and Tenofovir Versus Zidovudine in Second-line Antiretroviral Therapy Regimens for the Public Health Approach in Sub-Saharan Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Infectious Diseases Institute, Uganda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial evaluates options for second-line antiretroviral therapy in patients failing on a
      non-nucleoside reverse transcriptase inhibitor (NNRTI) and tenofovir (TDF)-based first-line
      regimen in the setting of the public health approach in sub-Saharan Africa (with assumed
      substantial nucleoside reverse transcriptase inhibitor (NRTI) cross-resistance). The trial
      tests two hypotheses. Firstly that a regimen of dolutegravir (DTG) with two NRTIs is
      non-inferior to a regimen of ritonavir-boosted darunavir (DRV/r) with two NRTIs. Secondly
      that continuing an NRTI regimen of TDF and lamivudine (3TC) is non-inferior to switching to
      zidovudine (ZDV) and 3TC.

      The trial is a parallel group, open-label, multi-centre, factorial (2X2) randomised,
      controlled trial. Patients will be randomised to either DTG or DRV/r with a second
      randomisation to ZDV and 3TC or TDF and 3TC. Treatment efficacy will be monitored by testing
      viral load (VL). Analyses will compare DRV/r with DTG; and ZDV/3TC with TDF/3TC by intention
      to treat analysis on the primary outcome parameter of plasma VL below 400 copies/ml at 48
      weeks. Trial follow-up will continue to 96 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 20, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma viral load &lt; 400 copies/ml at 48 weeks</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma viral load &lt; 1000 copies/ml</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma viral load &lt; 400 copies/ml at 96 weeks</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma viral load &lt; 50 copies/ml</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma viral load rebound (≥ 1000 copies/ml, confirmed)</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma viral load rebound (≥ 400 copies/ml, confirmed)</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma viral load rebound (≥ 50 copies/ml, confirmed)</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load rebound (≥ 1000 copies/ml, confirmed) with ≥ 1 major resistance mutation (IAS list) to DRV or DTG</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load rebound (≥ 1000 copies/ml, confirmed) with intermediate or high-level resistance (Stanford algorithm) to DRV or DTG</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load rebound (≥ 1000 copies/ml, confirmed) with intermediate or high-level resistance (Stanford algorithm) to both zidovudine and tenofovir</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ cell count change from baseline</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident (new or recurrent) WHO stage 4 event</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident serious non-AIDS event</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to new or recurrent WHO Stage 4 event, serious non-AIDS event, or death</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or 4 clinical adverse events</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3 or 4 clinical adverse events (possibly, probably or definitely related to ART)</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>48 and 96 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Darunavir/r Zidovudine Lamivudine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Darunavir 800mg once daily Ritonavir 100mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darunavir/r Tenofovir Lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Darunavir 800mg once daily Ritonavir 100mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dolutegravir Zidovudine Lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dolutegravir 50mg once daily Zidovudine 300mg twice daily Lamivudine 150mg twice daily Combination given for 96 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dolutegravir Tenofovir Lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dolutegravir 50mg once daily Tenofovir 300mg once daily Lamivudine 300mg once daily Combination given for 96 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>Antiretroviral therapy</description>
    <arm_group_label>Darunavir/r Tenofovir Lamivudine</arm_group_label>
    <arm_group_label>Darunavir/r Zidovudine Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Antiretroviral therapy</description>
    <arm_group_label>Darunavir/r Tenofovir Lamivudine</arm_group_label>
    <arm_group_label>Darunavir/r Zidovudine Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <description>Antiretroviral therapy</description>
    <arm_group_label>Dolutegravir Tenofovir Lamivudine</arm_group_label>
    <arm_group_label>Dolutegravir Zidovudine Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
    <description>Antiretroviral therapy</description>
    <arm_group_label>Darunavir/r Zidovudine Lamivudine</arm_group_label>
    <arm_group_label>Dolutegravir Zidovudine Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>Antiretroviral therapy</description>
    <arm_group_label>Darunavir/r Tenofovir Lamivudine</arm_group_label>
    <arm_group_label>Dolutegravir Tenofovir Lamivudine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Antiretroviral therapy</description>
    <arm_group_label>Darunavir/r Tenofovir Lamivudine</arm_group_label>
    <arm_group_label>Darunavir/r Zidovudine Lamivudine</arm_group_label>
    <arm_group_label>Dolutegravir Tenofovir Lamivudine</arm_group_label>
    <arm_group_label>Dolutegravir Zidovudine Lamivudine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, age 12 years and above

          2. Body weight at least 40kg

          3. Taking a tenofovir plus lamivudine/emtricitabine plus NNRTI-based regimen continuously
             for a total period of at least 6 months

          4. Good adherence to ART, defined as missing medication on no more than 3 days in the one
             month prior to screening. [Patients who do not have good adherence should be given
             adherence counselling and re-assessed after an interval of not less than 4 weeks].

          5. HIV treatment failure defined by virological criteria (modified from WHO 2016
             criteria); Viral load ≥ 1000 copies/ml at screening AND EITHER Viral load ≥ 1000
             copies/ml on the previous test, taken after at least 6 months on ART, and at no more
             than 6 months prior to screening and at no less than 4 weeks prior to screening, with
             adherence counselling given after the previous test OR Viral load ≥ 1000 copies/ml on
             a confirmatory test taken no less than 4 weeks after screening with adherence
             counselling given after the screening test

          6. If a woman of childbearing potential, must be willing to use effective contraception.
             [Childbearing potential is defined as being not premenarchal; not post-menopausal (&gt;
             12 months of spontaneous amenorrhea and ≥45 years of age); and not permanently
             sterilised].

          7. Willing and able to provide written informed consent

          8. Able to attend regular study follow-up visits

        Exclusion Criteria:

          1. Prior use of protease inhibitor or integrase inhibitor therapy

          2. Requirement for concomitant medication with known major interactions with study drugs
             for which drug substitutions or dose alterations are not available or acceptable (if
             the patient requires rifamycin-based TB treatment, rifabutin must be available at the
             site).

          3. Women who are currently pregnant or breastfeeding.

          4. Severe hepatic impairment (with ascites and/or encephalopathy)

          5. ALT &gt; 5 times upper limit of normal

          6. Estimated glomerular filtration rate (eGFR) &lt; 50 ml/min/1.73m2 at screening calculated
             using the CKD-EPI equation

          7. Current participation in another clinical trial or research protocol (may be permitted
             in some circumstances; but must first be discussed with the NADIA Chief Investigator)

          8. Life expectancy of less than one month in the opinion of the treating physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Paton, MD</last_name>
    <role>Study Director</role>
    <affiliation>National University, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas Paton, MD</last_name>
    <phone>+65 6772 4380</phone>
    <email>nick_paton@nuhs.edu.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anchilla Banegura, MPH</last_name>
    <phone>+256 312 307 000</phone>
    <phone_ext>219</phone_ext>
    <email>abanegura@idi.co.ug</email>
  </overall_contact_backup>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 13, 2019</study_first_submitted>
  <study_first_submitted_qc>June 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 17, 2019</study_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

